Medigen Vaccine Biologics Corp (高端疫苗) yesterday reported higher neutralizing antibody levels in people who were given its COVID-19 vaccine as a booster after two AstraZeneca doses, the company said.
In a trial of 200 participants who received Medigen’s COVID-19 vaccine, neutralizing antibodies against the Omicron variant of SARS-CoV-2 grew by 5.7 times one month after being administered, Taoyuan General Hospital said.
Medigen said that the results have been submitted to medRxiv, an online platform for researchers to share complete but unpublished papers.
Photo: Chu Pei-hsiung, Taipei Times
Another trial conducted by National Taiwan University Hospital showed that among 45 participants who received three doses of the Medigen vaccine, the level of neutralizing antibodies against the Omicron variant gradually fell, similar to those who received three doses of mRNA COVID-19 vaccines such as those made by Pfizer-BionNTech and Moderna Inc.
“This result indicates that our vaccine, as a booster shot, provided protection against the Omicron variant to some degree,” Medigen said.
The company said that people who have received adenovirus-based vaccines, such as the one made by AstraZeneca, or mRNA-based vaccines could consider taking the Medigen vaccine as a third shot given its safety profile, mild side effects and immunogenicity.
Medigen’s vaccine is a protein subunit vaccine, developed by recombinant technology. It comprises the recombinant spike protein of SARS-CoV-2 as the antigen to help a person’s body recognize the virus if a person becomes infected.
The company said that it would recruit 960 participants for a “mix-and-match” clinical trial in which it plans to test the safety and immunogenicity of different combinations of multiple brands of COVID-19 vaccines.
Medigen has received a subsidy of US$2.3 million from the Coalition for Epidemic Preparedness Innovations, an international foundation, to conduct the trial.
The trial is to be carried out in four hospitals, and recruitment of participants has begun, it said.
As of Sunday, 1.51 million people had received two doses of Medigen’s vaccine, accounting for four percent of 36.17 million who had received two COVID-19 shots, while 112,838 people had chosen the vaccine as booster shot, Centers for Disease Control data showed.
The US dollar was trading at NT$29.7 at 10am today on the Taipei Foreign Exchange, as the New Taiwan dollar gained NT$1.364 from the previous close last week. The NT dollar continued to rise today, after surging 3.07 percent on Friday. After opening at NT$30.91, the NT dollar gained more than NT$1 in just 15 minutes, briefly passing the NT$30 mark. Before the US Department of the Treasury's semi-annual currency report came out, expectations that the NT dollar would keep rising were already building. The NT dollar on Friday closed at NT$31.064, up by NT$0.953 — a 3.07 percent single-day gain. Today,
‘SHORT TERM’: The local currency would likely remain strong in the near term, driven by anticipated US trade pressure, capital inflows and expectations of a US Fed rate cut The US dollar is expected to fall below NT$30 in the near term, as traders anticipate increased pressure from Washington for Taiwan to allow the New Taiwan dollar to appreciate, Cathay United Bank (國泰世華銀行) chief economist Lin Chi-chao (林啟超) said. Following a sharp drop in the greenback against the NT dollar on Friday, Lin told the Central News Agency that the local currency is likely to remain strong in the short term, driven in part by market psychology surrounding anticipated US policy pressure. On Friday, the US dollar fell NT$0.953, or 3.07 percent, closing at NT$31.064 — its lowest level since Jan.
The New Taiwan dollar and Taiwanese stocks surged on signs that trade tensions between the world’s top two economies might start easing and as US tech earnings boosted the outlook of the nation’s semiconductor exports. The NT dollar strengthened as much as 3.8 percent versus the US dollar to 30.815, the biggest intraday gain since January 2011, closing at NT$31.064. The benchmark TAIEX jumped 2.73 percent to outperform the region’s equity gauges. Outlook for global trade improved after China said it is assessing possible trade talks with the US, providing a boost for the nation’s currency and shares. As the NT dollar
The Financial Supervisory Commission (FSC) yesterday met with some of the nation’s largest insurance companies as a skyrocketing New Taiwan dollar piles pressure on their hundreds of billions of dollars in US bond investments. The commission has asked some life insurance firms, among the biggest Asian holders of US debt, to discuss how the rapidly strengthening NT dollar has impacted their operations, people familiar with the matter said. The meeting took place as the NT dollar jumped as much as 5 percent yesterday, its biggest intraday gain in more than three decades. The local currency surged as exporters rushed to
RSS